VRG Therapeutics Announces Monthly Dosing for Its Lead Program Targeting Kv1.3 for the Treatment of Atopic Dermatitis and Other Chronic Inflammatory Diseases
Kv1.3
Conference
November 3, 2023
By VRG Therapeutics
Meet in Italy - Meet the startup: Vrg Therapeutics
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.